Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $296,661.86 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 3,203 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now directly owns 18,270 shares of the company’s stock, valued at $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ariel Hurley also recently made the following trade(s):

• On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The stock was sold at an average price of $100.00, for a total value of $225,000.00.
• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Stock Performance

Blueprint Medicines stock opened at $88.54 on Friday. The firm has a market capitalization of $5.66 billion, a P/E ratio of -81.98 and a beta of 0.62. The stock has a fifty day moving average price of $99.49 and a 200 day moving average price of $94.31. Blueprint Medicines Co. has a 52 week low of $80.68 and a 52 week high of $121.90. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities research analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on BPMC shares. Stephens reissued an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday. Piper Sandler raised their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average target price of $123.83.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in BPMC. Mirae Asset Global Investments Co. Ltd. increased its stake in Blueprint Medicines by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,291 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 422 shares during the last quarter. US Bancorp DE increased its stake in Blueprint Medicines by 147.6% during the third quarter. US Bancorp DE now owns 11,971 shares of the biotechnology company’s stock worth $1,107,000 after acquiring an additional 7,137 shares during the last quarter. M&G PLC acquired a new stake in Blueprint Medicines during the third quarter worth about $9,101,000. Covestor Ltd increased its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in Blueprint Medicines during the third quarter worth about $999,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.